Alzheimer’s Disease

TORONTO, Canada, July 15, 2026 Cumulus Neuroscience has presented new clinical findings at the Alzheimer’s Association International Conference (AAIC)...

LOS ANGELES, Calif., July 14, 2026 Spinogenix, Inc. has announced encouraging long-term clinical data demonstrating that its investigational therapy...

LONDON, United Kingdom, July 15, 2026 New research presented at the Alzheimer’s Association International Conference (AAIC) 2026 has revealed...

NEWTON, Mass., July 15, 2026 Acumen Pharmaceuticals presented new preclinical and clinical research at the Alzheimer’s Association International Conference...

BOCA RATON, Fla., July 15, 2026 INmune Bio announced the publication of a peer-reviewed preclinical study in the Journal...

CAMBRIDGE, Mass., July 14, 2026 Biogen announced positive Phase 2 CELIA study results demonstrating that investigational antisense oligonucleotide therapy...

CAMBRIDGE, Mass., July 14, 2026 ProMIS Neurosciences presented the first human evidence that its investigational Alzheimer’s disease therapy PMN310...

TOKYO, Japan & CAMBRIDGE, Mass., July 13, 2026 Eisai Co., Ltd. and Biogen Inc. have achieved a major regulatory...

OSAKA, Japan; CAMBRIDGE, Massachusetts; JAKARTA, Indonesia — July 13, 2026 Takeda has entered into a landmark collaboration with the...

FREMONT, California, July 13, 2026 Alamar Biosciences has partnered with leading U.S. research universities to launch a national-scale proteomics...